Sponsor: 
GlaxoSmithKline Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Combination vaccines

Registered for use in infants and children aged ≥6 weeks.

DTPa-hepB-IPV-Hib — diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccine

The vaccine consists of both a 0.5 mL monodose pre-filled syringe and a vial containing a lyophilised pellet.

The pre-filled syringe contains:

  • ≥30 IU diphtheria toxoid
  • ≥40 IU tetanus toxoid
  • 25 µg pertussis toxoid
  • 25 µg filamentous haemagglutinin
  • 8 µg pertactin
  • 10 µg recombinant hepatitis B surface antigen (HBsAg)
  • 40 D-antigen units inactivated poliovirus type 1 (Mahoney)
  • 8 D-antigen units inactivated poliovirus type 2 (MEF-1)
  • 32 D-antigen units inactivated poliovirus type 3 (Saukett)

Adsorbed onto aluminium hydroxide/phosphate.

Also contains traces of:

  • formaldehyde
  • polysorbate 80
  • polysorbate 20
  • polymyxin
  • neomycin

The vial containing a lyophilised pellet contains:

  • 10 µg purified Hib capsular polysaccharide conjugated to 20–40 µg tetanus toxoid

May contain yeast proteins.

The product information and consumer medicine information for Infanrix hexa have more details.

Audience: 
Infants and children
Previous

Infanrix

Next

Infanrix IPV

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018

Definitions

DTPa
diphtheria-tetanus-acellular pertussis vaccine
IPV
inactivated poliomyelitis vaccine
IU
international units
HBsAg
hepatitis B surface antigen